Showing results (1761-1770 of 1,853) with videos related to

Sort By:
Pageof 186
Plos Genetics|November 6, 2015
A Hereditary Enteropathy Caused by Mutations in the SLCO2A1 Gene, Encoding a Prostaglandin TransporterJunji Umeno, Tadakazu Hisamatsu, Motohiro Esaki, et al.
Medrxiv : the Preprint Server for Health Sciences|August 23, 2023
Plasma CXCL8 and MCP-1 as biomarkers of latent tuberculosis infectionSivaprakasam T Selvavinayagam, Bijulal Aswathy, Yean K Yong, et al.
Journal of Gastroenterology|January 10, 2018
Clinical features of chronic enteropathy associated with SLCO2A1 gene: a new entity clinically distinct from Crohn's diseaseJunji Umeno, Motohiro Esaki, Atsushi Hirano, et al.
Gastrointestinal Endoscopy|June 1, 2023
Effectiveness of endoscopic resection for colorectal neoplasms in ulcerative colitis: a multicenter registration studyMinami Hirai, Shunichi Yanai, Reiko Kunisaki, et al.
International Journal of Clinical Oncology|August 28, 2024
Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON studyYoshiyuki Yamamoto, Hiroki Yukami, Tatsuro Yamaguchi, et al.
Scientific Reports|July 30, 2024
Emergence of SARS-CoV-2 omicron variant JN.1 in Tamil Nadu, India - Clinical characteristics and novel mutationsSivaprakasam T Selvavinayagam, Sathish Sankar, Yean K Yong, et al.
The Journal of Allergy and Clinical Immunology|September 28, 2016
Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skinHitokazu Esaki, Patrick M Brunner, Yael Renert-Yuval, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 2, 2018
Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trialAtsuo Takashima, Kohei Shitara, Kazumasa Fujitani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 29, 2015
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)M-H Ryu, E Baba, K H Lee, et al.
Pageof 186